Art. -Nr.: HY-N0818

Chikusetsusaponin Iva

(Synonyms: Calenduloside F)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Chikusetsusaponin IVa is an orally active protein kinase activator. Chikusetsusaponin IVa binds to YAP with a K_D value of 0.388 mM. Chikusetsusaponin IVa reduces inflammatory mediators (IL-6, IL-10, COX-2) expression, NO production, promotes ROS generation, induces Apoptosis, inhibits MAPK, TAZ, and regulates Nrf2, JAK/STAT. Chikusetsusaponin Iva has anti-H9N2 AIV and anti-endometrial cancer activities. Chikusetsusaponin Iva shows anti-inflammatory, hepatoprotective and osteoprotective effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.61%
CAS. Nr.: 51415-02-2
Formel: C₄₂H₆₆O₁₄
Molecular Weight:794.97

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Chikusetsusaponin Iva Chemical Structure

CAS. Nr.: 51415-02-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	78.11 μM Compound: 11	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 20951582]
HL-60	IC₅₀	76.23 μM Compound: 11	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 20951582]
Neutrophil	IC₅₀	2.88 μM Compound: 6	Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils	[PMID: 21417387]
Neutrophil	IC₅₀	4.76 μM Compound: 6	Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins	[PMID: 21417387]

In Vitro

Chikusetsusaponin Iva (12.5-50 μM; 24 h) induces apoptosis in endometrial cancer cells (HEC1B) via promoting ROS production^[1].
Chikusetsusaponin IVa (3.75-60 μg/mL) shows inhibitory effects on H9N2 AIV in A549 cells, with TI values of 4.00 (co-treatment) and 6.29 (posttreatment)^[2].
Chikusetsusaponin IVa (50-200 μg/mL; 24 h) shows inhibitory effects on lipopolysaccharide-induced proinflammatory responses in THP-1 cells^[3].
Chikusetsusaponin IVa binds to YAP with a K_D of 0.388 mM^[4].
Chikusetsusaponin IVa (10-40 μM; 24 h) increases the viability of Palmitic acid (HY-N0830)-damaged HepG2 cells and primary mouse hepatocytes and reduces LDH levels in culture supernatants^[6].
Chikusetsusaponin Iva (3.125-12.5 μg/mL; 1 h) inhibits inflammatory responses in LPS-stimulated RAW264.7 cell line by inhibiting MAPK pathway^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HEC1B
Concentration:

0 μM, 12.5 μM, 25 μM, 50 μM
Incubation Time:

24 h
Result:

Decreased the phosphorylation levels of p38, ERK and JNK in a dose-dependent way.
Decreased the expression of Bcl-2 and increases the expression of Bax and cleaved caspase-3.

In Vivo

Chikusetsusaponin IVa (15-60 mg/kg; p.o.; once daily; 5 consecutive days) mitigates pulmonary impairment, improves the organism’s antioxidant activity, and regulates the Nrf2 and MAPK signaling pathways in lung tissue of H9N2 AIV-infected mice^[2].
Chikusetsusaponin IVa (10-40 mg/kg; p.o.; daily; 14 days after BDL) significantly alleviates liver fibrosis and injury in CCl₄ (HY-Y0298)-challenged and bile duct ligation (BDL)-induced liver fibrosis mouse models by downregulating YAP and TAZ expression^[4].
Chikusetsusaponin IVa (50-100 mg/kg; from day 28 to day 40) shows anti-inflammatory and osteoprotective effects on rheumatoid arthritis via the JAK/STAT signaling pathway in mice^[5].
Chikusetsusaponin IVa (50 mg/kg; i.g.; 8 weeks) can improve the symptoms of mice with high-fat diet (HFD)-induced metabolic dysfunction-associated steatotic liver disease (MASLD)^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

DBA 1/J male mice (18-22 g, 6-8 weeks old) + Collagen (HY-NP102)-induced arthritis (CIA) model^[5]
Dosage:

50 mg/kg、100 mg/kg
Administration:

days 28-40
Result:

Significantly reduced the arthritis index, hind paw thickness, and the number of swollen joints.
Decreased the immune organ index in a dose-dependent manner.
Reduced the concentration of inflammatory factors in peripheral serum and suppressed the mRNA expression of these factors in the spleen.
Inhibited the protein expression level of the JAK/STAT pathway.

Animal Model:

C57BL/6J male mice (weight 20 g, 8-12 weeks old) + high-fat diet-induced metabolic dysfunction-associated fatty liver disease (MASLD) model^[6]
Dosage:

50 mg/kg
Administration:

Intragastric administration, 8 weeks
Result:

Significantly reduced body weight and liver weight gains.
Decreased serum aspartate transaminase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (γ-GT), triacylglycerol (TG), total cholesterol (CHO), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and nonesterified fatty acids (NEFAs) levels. Alleviated HFD-induced hepatic steatosis, inflammation, and fibrosis.
Improved glucose tolerance and insulin resistance.

Chemical Information

CAS. Nr. 51415-02-2
Appearance Solid
Molecular Weight 794.97
Formel C₄₂H₆₆O₁₄
Color White to off-white
SMILES

O=C([C@]1(CCC(C)(C)C2)[C@]2([H])C3=CC[C@@]4([H])[C@@](C)(CC[C@]5([H])[C@@]4(CC[C@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6C(O)=O)C5(C)C)C)[C@]3(C)CC1)O[C@@H]([C@@H]([C@@H](O)[C@@H]7O)O)O[C@@H]7CO
Synonyms

Calenduloside F
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May:155:104751. PMID: 32151678
Int Immunopharmacol

CHS-Ⅳa activates the IGF1R/PI3K signal pathway with inhibited pyroptosis of endometrial stromal cells and progress of endometriosis. [Abstract]

2024 Nov 2;143(Pt 3):113527. PMID: 39488924

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (125.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2579 mL

6.2895 mL

12.5791 mL

5 mM

0.2516 mL

1.2579 mL

2.5158 mL

10 mM

0.1258 mL

0.6290 mL

1.2579 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xu G, et al. Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J Biosci. 2020 Sep 28;76(3-4):103-110. [Content Brief]

[2]. Dai Q, et al. Chikusetsusaponin IVa Targets Nrf2 to Inhibit H9N2 Avian Influenza Virus Infection. Pharmacognosy Magazine, 2024: 09731296241277316.

[3]. Wang H, et al. Inhibitory effects of Chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cells. Int J Immunopathol Pharmacol. 2015 Sep;28(3):308-17. [Content Brief]

[4]. Gao K, et al. Chikusetsusaponin IVa targeted YAP as an inhibitor to attenuate liver fibrosis and hepatic stellate cell activation. Chin Med. 2025 Mar 17;20(1):36. [Content Brief]

[5]. Guo X, et al. Anti-inflammatory and osteoprotective effects of Chikusetsusaponin Ⅳa on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine. 2021 Dec;93:153801. [Content Brief]

[6]. Liu YW, et al. Identification of chikusetsusaponin IVa as a novel lysine-specific demethylase 1 inhibitor that ameliorates high fat diet-induced MASLD in mice. Acta Pharmacol Sin. 2025 Mar;46(3):632-652. [Content Brief]

[7]. Xu G, Lei H, Yuan Q, Chen H, Su J. Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J Biosci. 2020 Sep 28;76(3-4):103-110. [Content Brief]

[8]. Cui J, et al. Insulinotropic effect of Chikusetsu saponin IVa in diabetic rats and pancreatic β-cells. J Ethnopharmacol. 2015 Apr 22;164:334-9. [Content Brief]

[9]. Dahmer T, et al. Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Maté). J Med Food. 2012 Dec;15(12):1073-80. [Content Brief]

[10]. Li Y, et al. Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects. J Pharm Pharmacol. 2015 Jul;67(7):997-1007. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2579 mL	6.2895 mL	12.5791 mL	31.4477 mL
	5 mM	0.2516 mL	1.2579 mL	2.5158 mL	6.2895 mL
	10 mM	0.1258 mL	0.6290 mL	1.2579 mL	3.1448 mL
	15 mM	0.0839 mL	0.4193 mL	0.8386 mL	2.0965 mL
	20 mM	0.0629 mL	0.3145 mL	0.6290 mL	1.5724 mL
	25 mM	0.0503 mL	0.2516 mL	0.5032 mL	1.2579 mL
	30 mM	0.0419 mL	0.2097 mL	0.4193 mL	1.0483 mL
	40 mM	0.0314 mL	0.1572 mL	0.3145 mL	0.7862 mL
	50 mM	0.0252 mL	0.1258 mL	0.2516 mL	0.6290 mL
	60 mM	0.0210 mL	0.1048 mL	0.2097 mL	0.5241 mL
	80 mM	0.0157 mL	0.0786 mL	0.1572 mL	0.3931 mL
	100 mM	0.0126 mL	0.0629 mL	0.1258 mL	0.3145 mL

Keywords

Chikusetsusaponin Iva

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Chikusetsusaponin Iva

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Pain-Related Compound Library

Anti-Ovarian Cancer Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Chikusetsusaponin Iva

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Chikusetsusaponin Iva Related Classifications

HY-N0818 Related Classifications